Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-242 in Sepsis-Induced Cardiovascular and Respiratory Failure
NCT00633477Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of resatorvid in sepsis, septic shock, respiratory failure, sponsored by Takeda. Started Feb 2008; status: terminated.
02
Drugs
resatorvid
03
Conditions
sepsisseptic shockrespiratory failure
Beyond the preview
Go deeper on NCT00633477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633477.